{
  "ticker": "INSM",
  "company_name": "Insmed Incorporated",
  "sector": "Healthcare",
  "industry": "Biotechnology",
  "analysis_date": "2025-12-18",
  "business_quality_score": 1,
  "financial_health_score": 5.3,
  "valuation_score": 5,
  "growth_score": 10,
  "sentiment_score": 9,
  "institutional_score": 10,
  "risk_score": 8.7,
  "conviction_score": 62.8,
  "conviction_tier": "MEDIUM",
  "bull_case": "Quality healthcare company with solid growth",
  "bear_case": "Sector rotation risk",
  "market_cap": 35520696320,
  "pe_ratio": null,
  "debt_to_equity": 78.274,
  "profit_margin": -2.6482801,
  "revenue_growth": 0.524,
  "current_price": 166.55,
  "analyst_target": 218.88889,
  "recommendation": "strong_buy",
  "position_size_modifier": 1.128
}